Keros Therapeutics Inc (NASDAQ:KROS) currently has a daily average trading volume of 1.07M but it saw 624935 shares traded in last market. With a market cap of 551.96M USD, the company’s current market price of $13.59 came rising about 0.89 while comparing to the previous closing price of $13.47. In past 52 weeks, the stock remained buoying in the range of price level as high as $72.37 and as low as $9.12.
Taking a look at 20-day trading activity of Keros Therapeutics Inc (KROS) gives us an average price of $14.08, while its current price level is -81.22% below from 52-week high level whereas it is 49.01% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $12.33 while that of 200 days or SMA-200 reads an average of $33.46. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.09% during that period while stretching the period over a month that decreases to 4.41%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 52.87 which implies that the stock is in neutral territory.
Wedbush downgraded its recommendation for the stock as a “Neutral” from “Outperform” on January 17, 2025 while assigning a price target of $15. Oppenheimer issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $102 and $63.
Over the week, KROS’s stock price is moving -0.88% down while it is 6.67% when we observe its performance for the past one month. Year-to-date it is -14.15% down and over the past year, the stock is showing a downside performance of -74.96%.
Currently, Keros Therapeutics Inc’s total number of outstanding shares is 40.56M with 2.27% of that held by the insiders while 109.82% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 0.57% and return on equity (ROE) at 0.71%. Stock’s beta reads 1.30. Stock has a price to book (P/B) ratio of 0.76 while price to sale or P/S ratio amounts to 2.57. Its return on asset (ROA) is 0.66% on average.
